ArticleJournal of managed care & specialty pharmacy2026
Real-world switching and switch-back patterns among patients transitioning from adalimumab to biosimilars in the United States (February 2023 to August 2025).
Karen Gilbert Farrar et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.